Resistant fusarium keratitis progressing to endophthalmitis

Eye and Contact Lens

Volumn 38, Issue 5, 2012, Pages 331-335

  Edelstein, Sean L ^a   Akduman, Levent ^a   Durham, Benjamin H ^a   Fothergill, Annette W ^b   Hsu, Hugo Y ^c  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Endophthalmitis; Fusarium; Keratitis; Multidrug resistant

Indexed keywords

AMPHOTERICIN B; CYCLOSPORIN A; FLUCONAZOLE; NATAMYCIN; POSACONAZOLE; VORICONAZOLE;

ADULT; ANTIFUNGAL SUSCEPTIBILITY; ANTIMICROBIAL THERAPY; B SCAN; CASE REPORT; CONIDIUM; CONJUNCTIVA DISEASE; CORNEA ULCER; DESCEMET MEMBRANE; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EYE EXAMINATION; FUNGAL DETECTION; FUNGAL ENDOPHTHALMITIS; FUNGUS CULTURE; FUNGUS HYPHAE; FUSARIOSIS; FUSARIUM KERATITIS; FUSARIUM SOLANI; GRANULATION TISSUE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTRAOPERATIVE PERIOD; KERATOMYCOSIS; MALE; MEMBRANE DAMAGE; PATIENT REFERRAL; PENETRATING KERATOPLASTY; POSTOPERATIVE CARE; PRIORITY JOURNAL; REVIEW; SLIT LAMP; SYSTEMIC THERAPY; VITRECTOMY; VITREOUS OPACITY;

ANTIFUNGAL AGENTS; COUMARINS; DISEASE PROGRESSION; DRUG RESISTANCE, MULTIPLE, FUNGAL; ENDOPHTHALMITIS; EYE ENUCLEATION; EYE INFECTIONS, FUNGAL; FUSARIOSIS; HUMANS; KERATITIS; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84865964979     PISSN: 15422321     EISSN: 1542233X     Source Type: Journal    
DOI: 10.1097/ICL.0b013e318235c5af     Document Type: Review

References (33)

1. Rosa RH, Miller D, Alfonso EC. The changing spectrum of fungal keratitis in south Florida. Ophthalmology 1994;101:1005-1013.
2. Wong TY, Fong KS, Tan DT. Clinical and microbial spectrum of fungal keratitis in Singapore: A 5-year retrospective study. Int Ophthalmol 1997;21: 127-130.
3. Jurkunas U, Behlau I, Colby K. Fungal keratitis: Changing pathogens and risk factors. Cornea 2009;28:638-643.
4. Dursun D, Fernandez V, Miller D, et al. Advanced Fusarium keratitis progressing to endophthalmitis. Cornea 2003;22:300-303.
5. Alfonso EC, Cantu-Dibildox J, Munir WM, et al. Insurgence of Fusarium keratitis associated with contact lens wear. Arch Ophthalmol 2006;124: 941-947.
6. Alfonso EC, Miller D, Cantu-Dibildox J, et al. Fungal keratitis associated with non-therapeutic soft contact lenses. Am J Ophthalmol 2006;142: 154-155.
7. Bernal MD, Acharya NR, Lietman TM, et al. Outbreak of Fusarium keratitis in soft contact lens wearers in San Francisco. Arch Ophthalmol 2006;124: 1051-1053.
8. Wong TY, Au Eong KG, Chan WK, et al. Fusarium keratitis following the use of topical antibiotic-corticosteroid therapy in traumatised eyes. Ann Acad Med Singapore 1996;25:862-865.
9. Gopinathan U, Garg P, Fernandes M, et al. The epidemiological features and laboratory results of fungal keratitis: A 10-year review at a referral eye care center in south India. Cornea 2002;21:555-559.
10. Clinical and Laboratory Standards Institute/National Committee for Clinical Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi; Approved Standard, 2nd ed. Document M38-A2. Wayne, PA: Clinical and Laboratory Standards Institute, 2008.
11. Tu EY, McCartney DL, Beatty RF, et al. Successful treatment of resistant ocular fusariosis with posaconazole (SCH-56592). Am J Ophthalmol 2007; 143:222-227.
12. Sponsel WE, Graybill JR, Nevarez HL, et al. Ocular and systemic posaconazole (SCH-56592) treatment of invasive Fusarium solani keratitis and endophthalmitis. Br J Ophthalmol 2002;86:829-830.
13. Lalitha P, Shapiro BL, Srinivasan M, et al. Antimicrobial susceptibility of Fusarium, Aspergillus, and other filamentous fungi isolated from keratitis. Arch Ophthalmol 2007;125:789-793.
14. Marangon FB, Miller D, Giaconi JA, et al. In vitro investigation of voriconazole susceptibility for keratitis and endophthalmitis fungal pathogens. Am J Ophthalmol 2004;137:820-825.
15. Marr KA, Carter RA, Crippa F, et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002;34:909.
16. Metcalf SC, Dockrell DH. Improved outcomes associated with advances in therapy for invasive fungal infections in immunocompromised hosts. J Infect 2007;55:287-299.
17. Alfonso EC, Galor A,Miller D. Fungal keratitis. In: Krachmer JH,MannisMJ, Holland EJ, eds. Cornea Volume One: Fundamentals, Diagnosis, and Management, 3rd ed. Philadelphia, PA, Elsevier Mosby, 2011, pp 1009-1022.
18. Jones DB, Forster RK, Rebell G. Fusarium solani keratitis treated with natamycin (pimaricin): Eighteen consecutive cases. Arch Ophthalmol 1972; 88:147-154.
19. Klont RR, Eggink CA, Rijs AJ, et al. Successful treatment of Fusarium keratitis with cornea transplantation and topical and systemic voriconazole. Clin Infect Dis 2005;40:e110-e112.
20. Rahman MR, Johnson GJ, Husain R, et al. Randomised trial of 0.2% chlorhexidine gluconate and 2.5% natamycin for fungal keratitis in Bangladesh. Br J Ophthalmol 1998;82:919-925.
21. Kalavathy CM, Parmar P, Kaliamurthy J, et al. Comparison of topical itraconazole 1% with topical natamycin 0.5% for the treatment of filamentous fungal keratitis. Cornea 2005;24:449-452.
22. Thomas PA. Current perspectives on ophthalmic mycoses. Clin Micriobiol Rev 2003;16:730-797.
23. Alfonso EC, Rosa RH, Miller D. Fungal keratitis. In: Krachmer JH, Manning MJ, Holland EJ, eds. Cornea, 2nd ed. Philadelphia, PA, Elsevier Mosby, 2005, pp 1101-1112.
24. Gianoli F, Guex-Crosier Y, Marchetti O, et al. Anterior segment necrosis in multidrug-resistant Fusarium keratomycosis: A case study [in French]. J Fr Ophtalmol 2005;28:498-501.
25. Sauer A, Abry F, Lhermitte B, et al. Purulent corneal melting secondary to multidrug-resistant Fusarium oxysporum aggravated by topical corticosteroid therapy [in French]. J Fr Ophtalmol 2008;31:534.e1-534.e5.
26. Guarro J, Rubio C, Gené J, et al. Case of keratitis caused by an uncommon Fusarium species. J Clin Microbiol 2003;41:5823-5826.
27. Chang DC, Grant GB, O'Donnell K, et al. Multistate outbreak of Fusarium keratitis associated with use of a contact lens solution. JAMA 2006;296: 953-963.
28. MacGowan AP, Wise R. Establishing MIC breakpoints and the interpretation of in vitro susceptibility tests. J Antimicrob Chemother 2001;48:17-28.
29. Espinel-Ingroff A, Canton E, Peman J. Updates in antifungal susceptibility testing of filamentous fungi. Curr Fungal Infect Rep 2009;3:133-141.
30. Espinel-Ingroff A, Johnson E, Hockey H, et al. Activities of voriconazole, itraconazole and amphotericin B in vitro against 590 moulds from 323 patients in the voriconazole phase III clinical studies. J Antimicrob Chemother 2008;61:616-620.
31. Pfaller MA, Diekema DJ, Ghannoum MA, et al. Wild-type MIC distribution and epidemiological cutoff values for Aspergillus fumigatus and three triazoles as determined by the Clinical and Laboratory Standards Institute broth microdilution methods. J Clin Microbiol 2009;47:3142-3146.
32. Espinel-Ingroff A, Dawson K, Pfaller M, et al. Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi. Antimicrob Agents Chemother 1995;39: 314-319.
33. Rex JH, Pfaller MA. Has antifungal susceptibility testing come of age? Clin Infect Dis 2002;35:982-989.